Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. reports developments in biotechnology and precision intracellular drug delivery through its proprietary Accum® platform. Company news centers on cancer-therapy applications, including antibody-drug conjugates, radiopharmaceutical and radio-immunoconjugate programs, and other complex biologics designed for intracellular and nuclear delivery.
Recurring updates also cover scientific advisory activity, industry presentations, collaboration work such as its program with Canadian Nuclear Laboratories, partnership outreach, and capital-structure actions including private placements, warrant amendments, and restricted stock unit grants.
Defence Therapeutics (DTCFF) released a CEO letter on September 8, 2026 outlining recent progress and strategic priorities.
New President and CEO Dr. Amie Phinney describes a sharpened focus on leveraging the proprietary Accum® drug-delivery platform in oncology. Following an earlier capital raise and additions to leadership, board, scientific staff and laboratory capabilities, the company plans to pursue growth through partnered programs and a focused internal pipeline. Development will concentrate on three areas: Accum®-enhanced antibody-drug conjugates (ADCs), Accum®-enabled radiotherapeutics, and defining the future of the clinical-stage AccuTOX® program.
The company is seeking revenue-generating ADC partnerships and licences, building a portfolio of Accum®-enabled radiotherapeutics toward clinical development, and undertaking a disciplined review of strategic options for AccuTOX®, including partnering, out-licensing or selective reactivation in melanoma.
Defence Therapeutics (DTCFF) updated investors on its March 6, 2026 Sharing Agreement with Sorbie Bornholm LP tied to a $6,000,000 subscription within a $9,595,000.25 private placement of 17,445,455 units at $0.55 per unit.
The Sharing Agreement provides for 18 monthly cash settlements benchmarked at $0.7332 per share, with each payment adjusted using a 20-day volume-weighted average price (20 Day VWAP) and a reference monthly amount of $333,333. If the 20 Day VWAP is below the benchmark, the Company receives less than $333,333; if above, it receives more. The Company has received the first Settlement of $182,623.49 as of August 14, 2026, against 606,060 Placement Shares released to SBLP. A remaining 10,303,031 Placement Shares are held in escrow, and 17 Settlement payments are still to be made.
Defence Therapeutics (OTCQB: DTCFF) announced an expansion of its radiopharmaceutical development strategy to evaluate both alpha-emitting and beta-emitting radioisotopes using its Accum® intracellular delivery platform. The initiative aims to broaden Accum®'s use in precision oncology by enhancing intracellular transport of radioactive payloads into cancer cells.
The program will study alpha emitters such as Actinium-225 and beta emitters such as Lutetium-177, generating comparative pharmacology, efficacy and safety data across both isotope classes. Ongoing preclinical work focuses on optimizing tumor cell accumulation, reducing off-target toxicity, and advancing Accum®-enabled radio-immunoconjugate candidates toward future clinical development.
Defence Therapeutics (OTCQB: DTCFF) appointed Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs, aiming to strengthen leadership as it advances its radiopharmaceutical drug conjugate (RDC) pipeline.
Dr. Simms has over 20 years of experience in targeted radiopharmaceuticals, including leadership roles at Fusion Pharmaceuticals, which was acquired by AstraZeneca in 2024 for approximately US$2 billion, as well as Abdera Therapeutics and the Centre for Probe Development and Commercialization. His background spans CMC strategy, manufacturing, isotope supply, radiochemistry and technical operations. Defence highlighted that his near-term focus will be selecting a lead RDC candidate, driving preclinical characterization, and establishing the CMC and manufacturing framework required to progress toward the clinic. The appointment follows the recent naming of Dr. Amie Phinney as President and CEO and the opening of a new office at McMaster Innovation Park in Hamilton.
Defence Therapeutics (CSE: DTC, OTCQB: DTCFF, FSE: DTC) appointed Dr. Amie Phinney as President and Chief Executive Officer, effective August 1, 2026, while founder Sébastien Plouffe became Executive Chairman, continuing to oversee strategy, financing, partnerships, and long-term growth.
Dr. Phinney joined Defence in 2025, serving as Strategy & Business Advisor and Board member, and brings over two decades of global experience across Abbott, AbbVie, Lakeside Discovery, adMare BioInnovations and Block Biosciences. Under her leadership, Defence plans to advance its Accum® intracellular drug-delivery platform across ADCs, radiotherapeutics and other targeted biologics, and expand strategic collaborations.
The company also granted 600,000 incentive stock options at an exercise price of $0.40 per share: 200,000 to Dr. Phinney (half vesting immediately, half after one year), 200,000 to an employee on the same terms, and 200,000 to the Executive Chairman, fully vested with a ten-year term.
Defence Therapeutics (OTCQB:DTCFF) opened a new office at McMaster Innovation Park in Hamilton, Ontario, to support its expanding Accum radiopharmaceutical and precision oncology platform.
The Hamilton site aims to enhance collaborations, access specialized radiopharma expertise, and strengthen development of ADCs, radiopharmaceuticals, and other complex biologics.
Defence Therapeutics (OTCQB:DTCFF) will participate in the BIO International Convention 2026 in San Diego from June 22-25. The company plans strategic partnership discussions focused on its Accum® intracellular delivery platform for ADCs, radiopharmaceuticals, biosimilars, and revitalizing existing or discontinued therapeutic assets.
Defence Therapeutics (OTCQB:DTCFF) appointed biopharma executive Dr John Beaver to its Board of Directors. He brings 20+ years of leadership at Biogen, AbbVie, and GlaxoSmithKline, spanning translational medicine, biomarkers, and clinical pharmacology.
Defence granted Dr Beaver 150,000 stock options, vested immediately at $0.60 per share for five years, and continues advancing its ACCUM® intracellular delivery platform across ADC and radiopharmaceutical programs.
Defence Therapeutics (OTCQB:DTCFF) appointed ADC pioneer Dr. John Lambert to its Board of Directors, effective immediately. Lambert brings 40+ years of antibody-drug conjugate experience, including leadership roles at ImmunoGen, whose ADC technologies contributed to therapies such as KADCYLA, SARCLISA and ELAHERE.
Defence granted Lambert 150,000 stock options, vesting immediately and exercisable at $0.58 per share for five years. The company continues advancing its ACCUM-enabled ADC and radiopharmaceutical programs to enhance intracellular delivery and treatment outcomes.
Defence Therapeutics (OTCQB:DTCFF) announced that Dr. Sarkis Meterissian resigned from its Board of Directors to join the company’s Scientific Advisory Board (SAB). The SAB now includes Rob Leanna, PhD, Danny Chui, PhD, Brendan Hussey, PhD, and Dr. Meterissian.
The company also granted 150,000 incentive stock options to employees and consultants under its omnibus incentive plan, vested immediately and exercisable at $0.58 per share for five years from the grant date.